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Abstract
Purpose Nitric oxide (NO) synthesised by endothelial NO
synthase (eNOS) is a potent regulator of internal haemodynamics.
A polymorphism in intron 4 of the eNOS is associated
with different vascular disorders. We investigated the
potential involvement of this polymorphism in idiopathic
and secondary osteonecrosis of the femoral head (ONFH)
in Polish patients.
Methods We performed a study involving 68 patients with
ONFH (45 idiopathic and 23 secondary) and 100 healthy
controls. All subjects were genotyped for the eNOS4 poly-
morphism by the polymerase chain reaction followed by
agarose gel electrophoresis.
Results The analysis revealed that the frequencies of
eNOS4 genotypes were significantly different in ONFH
patients (both idiopathic and secondary) than in controls.
The frequencies of the 4a allele were significantly higher
in the total group of patients versus controls [22.79 vs 9 %,
p=0.00039, odds ratio (OR) 2.98]. In subgroup analysis
the 4a allele increased significantly in both idiopathic (20
vs 9 %, p=0.0074, OR=2.52) and secondary (28.26 vs
9 %, p=0.00047, OR=3.98) ONFH patients compared to
control subjects. The frequency of the 4a/b genotype in the
total group of patients (36.76 vs 16 %, p=0.0011, OR=3.24)
as well as patients with idiopathic (35.56 vs 16 %, p=0.0069,
OR=2.96) and secondary (39.13 vs 16 %, p=0.0073, OR=
3.89) ONFH was higher than in the control group.
Conclusions There was a significantly higher frequency of
eNOS 4a allele carriers among the total group of patients as
well as in idiopathic and secondary ONFH. This suggests
that the eNOS gene polymorphism may be associated with
increased risk of ONFH.
Introduction
The prevalence of osteonecrosis of the femoral head
(ONFH) is not well known. It is assumed that from 10,000
to 20,000 new cases of ONFH are annually identified in the
USA [24]. ONFH occurs mainly in young and active pa-
tients, usually between 30 and 50 years old. Osteonecrosis
of the femoral head accounts for 10 % of total hip
arthroplasties performed every year in the USA and Western
Europe [24].
ONFH is a disease with multiple aetiologies with the
death of osteocytes as the end stage of different pathological
processes [2]. The most common causes of secondary
ONFH are steroids, alcohol abuse, haemoglobinopathies,
hyperlipidaemia, storage diseases, pregnancy, hyperbarism,
solid organs and bone marrow transplantations, and chemo-
therapy [2].
One of the possible causes of ONFH is occlusion of
vessels responsible for blood supply of the femoral head
because of thrombophilia and/or hypofibrinolysis [13]. Sev-
eral investigations have been performed to reveal the genetic
background of thrombophilia-related ONFH [9]. Recently
the relationship between endothelial nitric oxide synthase
(eNOS) polymorphisms and ONFH has been reported [10,
14]. Nitric oxide (NO) is an intracellular messenger which
plays an important role in homoeostasis, vascular system
and bone turnover [21]. Nitric oxide inhibits platelet activa-
tion, adhesion and aggregation [19]. It was also revealed
that NO is a vasodilatation molecule, and NO deficiency
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causes vasospasm [5]. Impairment in NO production dimin-
ishes angiogenesis [18]. Nitric oxide controls microvascular
permeability [6]. It was reported that NO regulates bone
mass and bone turnover through effects on osteoclast and
osteoblast activity [20] and inhibits osteoclasis [15].
Nitric oxide is synthesised from L-arginine by three
isoforms of synthases (NOS): neuronal (nNOS), inducible
(iNOS) and endothelial (eNOS). Nitric oxide synthase
isoforms share 50 % homology and are encoded by different
genes [17]. Endothelial nitric oxide synthase is predominantly
a constitutive isoform expressed in normal adult bone [8].
Human eNOS is encoded by a gene located on chromosome
7q35-36 comprising 26 exons and 25 introns and its predom-
inant form has 133 kDa [1]. The enzymatic activity of the
constitutively expressed eNOS is controlled by intracellular
Ca2+ levels and other cofactors. After being released in endo-
thelial cells, NO diffuses rapidly through cell membranes and
relaxes neighbouring vascular smooth muscle cells through
the production of guanosine 3′,5′-cyclic monophosphate
(cGMP).
Over the last few years several polymorphisms of the eNOS
gene have been identified, and their association with various
diseases has been explored [25]. Most of the attention has
focused on a single nucleotide polymorphism in the promoter
region (T-786-C), a single nucleotide polymorphism in exon 7
(Glu296Asp) and a variable number of tandem repeats in
intron 4. In the 27-bp repeat in intron 4, two alleles have been
identified, the larger of which, eNOS4b, has five tandem 27-bp
repeats [GAAGTCTAGACCTGCTGC(A/G)GGGGTGAG]
and the smaller, eNOS4a, has four repeats. It was revealed that
NO levels were significantly lower in the subjects with the 4a
allele than in those without the presence of the 4a allele [23].
Nitric oxide plays a role in bone angiogenesis, thrombosis
and turnover, all of which are probably related to the patho-
genesis of osteonecrosis [4]. The aim of this study was to
investigate possible correlations between the eNOS intron 4
polymorphism and non-traumatic ONFH in Polish patients.
Subjects and methods
Patients
A group of 68 unrelated adults (106 hips) were involved in
this study. All patients were Caucasians of Polish origin
coming from the eastern part of Poland. Patients were admit-
ted to the Orthopaedic and Traumatology Department for
operative treatment of ONFH. ONFH was diagnosed by
clinical examination and radiographic analysis. Patients with-
out characteristic risk factors related to ON were classified as
having idiopathic ONFH (n=45). The cause of ONFH was
established in 23 patients: the use of corticosteroids (n=11),
chemotherapy (n=7), alcoholism (n=4) and renal
transplantation (n=1). These patients were classified as hav-
ing secondary ONFH. Patients with idiopathic and secondary
ONFH did not differ with respect to average age and gender
distribution. The Ficat and Arlet classification was used for
radiographic evaluation [7]. Anteroposterior (AP) and frog
view X-rays of both hips were done in all of the patients.
Magnetic resonance imaging (MRI) was performed to con-
firm the diagnosis of ONFH in patients without X-ray
changes (Figs. 1a, b and 2). ONFH was present in one hip
in 30 patients and in both hips in 38 patients (106 hips). Stage
I of ONFH according to Ficat and Arlet [7] was seen in 14
hips, II in 19 hips, III in 22 hips and IV in 51 hips. Healthy
control subjects (n=100) with no clinical signs and family
history of ONFH were recruited among blood donors and
hospital staff. All participants in the control group also came
from the eastern part of Poland.
A written informed consent for genetic studies was
obtained from all patients and members of the control group.
The study protocol was evaluated and approved by the
Ethics Committee at the Medical University in Lublin.
Determination of eNOS genotype
Genomic DNA was isolated from peripheral blood
leucocytes using the method described by Madisen et
al. [16] with minor modifications. For polymerase chain
reaction (PCR) amplification, two oligonucleotide primers
were used that flank the region of the 27-bp repeat
sequence in intron 4 of the eNOS gene. The forward
primer was 5′-AGGCCCTATGGTAGTGCCTTT-3′ and
the reverse primer was 5′-tctcttagtgctgtggtcac-3′. Geno-
mic DNA (300 ng) was amplified in a final reaction
Fig. 1 a X-ray of a 42-year-old patient with idiopathic ONFH of both
hips. b MRI scan presents the extent of osteonecrosis
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volume of 50 μl, containing 10 mM Tris pH 8.3, 50 mM
KCl, 1.5 mM MgCl2, 200 μM each dNTP, 1 μM of each
primer and 2 U Taq polymerase (all reagents from MBI
Fermentas). The reaction mixture was heated to 94 °C for
six minutes for denaturation and then subjected to 35 cycles at
94 °C for one minute, annealing at 56 °C for one minute and
extension at 72 °C for two minutes. Final extension was at
72 °C for seven minutes. The PCR products were analysed by
electrophoresis in 2.5 % agarose gels stained with ethidium
bromide (Fig. 3).
Statistical analysis
All calculations were performed using SPSS for Windows
17.0. Normally distributed data are presented as means±SD.
Genotype distribution and allele frequencies were compared
between groups using the χ2 test and Fisher’s exact test,
respectively. Odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated using relevant 2 × 2 contingency tables.
Results
We genotyped the eNOS intron 4 polymorphism in 68 patients
with ONFH and 100 healthy controls. Clinical characteristics
of the study group are summarised in Table 1. No significant
differences between groups with respect to age and gender
ratio were observed. Genotype and allele frequencies of
ONFH risk patients are showed in Tables 2 and 3. The
genotype frequencies of the analysed polymorphism were
in Hardy-Weinberg equilibrium. All alleles and genotypes
were observed in the ONFH and control groups, even the
rare 4a/a genotype. When compared to the control group
the frequency of the 4a allele was higher in the total group
of patients (22.79 vs 9 %, p=0.00039, OR=2.98, 95 % CI
1.59–5,59), idiopathic osteonecrosis (20 vs 9 %, p=
0.0074, OR=2.52, 95 % CI 1.24–5.13) and secondary
osteonecrosis subgroups (28.26 vs 9 %, p=0.00047, OR=
3.98, 95 % CI 1.78–8.9). The frequency of the 4a/a geno-
type was significantly higher in the secondary ONFH sub-
group than in controls (8.7 vs 1 %, p=0.036, OR=13.83,
95 % CI 1.16–164.4). The 4a/a genotype frequency tended
to be higher in other groups than in controls but was not
statistically significant. The frequency of the 4a/b genotype
was statistically significant in patients (36.76 vs 16 %, p=
0.0011, OR=3.24, 95 % CI 1.55–6.74), idiopathic (35.56
vs 16 %, p=0.0069, OR=2.96, 95 % CI 1.31–6.69) and
secondary (39.13 vs 16 %, p=0.0073, OR=3.89, 95 % CI
1.4–10.75) subgroups.
Discussion
Koo et al. [14] were the first to report on the relationship
between eNOS polymorphisms and ONFH. The study was
performed in Korean patients. They found significantly
higher frequencies of the 4a allele in the total group of
patients (6.8 vs 2.4 %, p=0.0345, OR=2.931) and idiopathic
ONFH subgroup (9.0 vs 2.4%, p=0.0297, OR=3.976) than in
the control group. The rare 4a/a genotype was not found in
patients with ONFH. The frequency of the the 4a/b genotype
in the total group of patients (13.6 vs 4.9 %, p=0.0302, OR=
3.083) as well as in patients with idiopathic ONFH (18.0 vs
4.9 %, p=0.0246, OR=4.302) was higher than in control
subjects. The frequency of the intron 4 polymorphism did
not differ when patients with ONFH secondary to steroids or
alcohol abuse were compared with controls. No other reports
on a relationship between the eNOS 4 intron polymorphism
and ONFH have as yet been published. Our study presents the
results in Caucasian patients and a control group coming from
one geographical region. We found higher frequencies of the
4a allele and 4a/b genotype in both the total group of patients
and the idiopathic ONFH group, but also in the secondary
ONFH subgroup. The rare 4a/a genotype was present in our
study and was statistically significantly more frequent in the
secondary ONFH subgroup. The differences in results show
the impact of ethnicity on the prevalence of the mutations
[22]. Our results show a strong association between the eNOS
polymorphism and ONFH. Our results support the
Fig. 2 X-ray of a 22-year-old patient with secondary steroid-induced
ONFH of both hips
Fig. 3 PCR product of the polymorphism in intron 4 of the eNOS gene
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conclusions of Koo et al. [14] that since the 4a polymorphism
is associated with reduced synthesis of eNOS a carrier state of
the 4a allele in intron 4 might be a genetic risk factor for
ONFH and could provide insight into the protective role of
NO in the pathogenesis of this condition.
Glueck et al. [10] reported an association between the T-
786-C eNOS polymorphism and idiopathic ONFH. Patients
differed in race: white 85 %, black 9 % and other 4 %. The
authors found a higher TT mutant allele frequency in the
idiopathic osteonecrosis group than in the race-, gender- and
age-matched control group (22 vs 3 %, OR=6.0, 95 % CI
2.51–14.4). In addition to this they did not find an associa-
tion of the T-786-C eNOS polymorphism and allele frequen-
cy between secondary ONFH and the race-, gender- and
age-matched control group. Patients with primary ONFH
had a higher frequency of mutant genotype and mutant
allele frequency than the secondary ONFH group. In com-
parison to the papers of Koo et al. [14] and Glueck et al.
[10], we found a positive correlation between higher fre-
quency of eNOS polymorphism and allele frequency in the
secondary ONFH group as well as in the idiopathic ONFH
group. An impairment of NO production may play a syner-
gistic role with other conditions in the development of
secondary ONFH. Our results suggest that the eNOS
polymorphism may contribute to the pathogenesis of both
idiopathic and secondary ONFH. Later studies revealed a
statistically significant correlation between the T-786-C
eNOS polymorphism and idiopathic as well as secondary
multifocal osteonecrosis [11]. The T-786-C eNOS polymor-
phism was reported as a potential cause of neuralgia-
inducing cavitational osteonecrosis of the jaws [12].
There were reports suggesting that smoking decreases
eNOS activity and may modify relations between polymor-
phisms and expression levels [3]. Both Koo et al. [14] and
Glueck et al. [10] revealed that smoking is a synergistic risk
factor for ONFH in association with the eNOS polymor-
phism in idiopathic ONFH. We observed more smokers in
the idiopathic ONFH group than in the secondary group, but
the relationship between smoking and the eNOS polymor-
phism was not studied because data about smoking in the
control group was lacking.
In conclusion, the eNOS 4a gene polymorphism was
associated with ONFH in Polish patients. Reduction in NO
production causes promotion of platelet recruitment, aggre-
gation and adhesion, impairing angiogenesis and reducing
bone formation. The eNOS polymorphism demonstrates a
mul t id i rec t ional cause of ONFH via the eNOS
Table 1 Characteristics of the
ONFH study group Total (n=68) Idiopathic (n=45) Secondary (n=23)
Gender (M/F) 56/12 (82.35 %/17.65 %) 38/7 (84.44 %/15.56 %) 18/5 (78.26 %/21.74 %)
Age (years) 44.98 (15–77) 44.42 (15–77) 46.08 (20–74)
Smoking 27 (39.7 %) 21 (46.66 %) 6 (26.06 %)
Diabetes mellitus 8 (11.76 %) 4 (8.88 %) 4 (17.39 %)
Coronary disease 3 (4.41 %) 2 (4.44 %) 1 (4.34 %)
Thrombosis 1 (1.47 %) 0 1 (4.34 %)
Leriche syndrome 1 (1.47 %) 1 (2.22 %) 0
Hypertension 13 (19.11 %) 8 (17.77 %) 5 (21.73 %)
Hyperlipidaemia 1 (1.47 %) 1 (2.22 %) 0
Table 2 Allele frequencies, OR and 95 % CIs of the eNOS polymor-











4a 18 (9 %) 31 (22.79 %)a 18 (20 %)b 13 (28.26 %)c
4b 182 (91 %) 105 (77.21 %) 72 (80 %) 33 (71.74 %)
a p=0.00039, OR=2.98, 95 % CI 1.59–5.59
b p=0.0074, OR=2.52, 95 % CI 1.24–5.13
c p=0.00047, OR=3.98, 95 % CI 1.78–8.9
Table 3 Genotype frequencies, OR and 95 % CIs of the eNOS











4a/a 1 (1 %) 3 (4.41 %) 1 (2.22 %) 2 (8.70 %)a
4a/b 16 (16 %) 25 (36.76 %)b 16 (35.56 %)c 9 (39.13 %)d
4b/b 83 (83 %) 40 (58.82 %) 28 (62.22 %) 12 (52.17 %)
a p=0.036, OR=13.83, 95 % CI 1.16–164.4
b p=0.0011, OR=3.24, 95 % CI 1.55–6.74
c p=0.0069, OR=2.96, 95 % CI 1.31–6.69
d p=0.0073, OR=3.89 95 % CI 1.4–10.75
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polymorphism. The eNOS polymorphism may be an inde-
pendent cause of idiopathic osteonecrosis and may be a
synergistic cause of secondary ONFH with other patho-
aetiologies of osteonecrosis. The strength of this study lies
in being the first to examine the association between the
eNOS polymorphism and ONFH in ethnically homoge-
neous Caucasians. Our study has some limitations. The
small sample size and investigation of unselected cases
may influence the results. Comparisons with other eNOS
polymorphisms were not examined. Despite these limitations,
the association of the eNOS gene intron 4 polymorphism with
ONFH susceptibility will strengthen our understanding of the
relationship between eNOS dysfunction and ONFH
pathogenesis.
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